Paradice Rebuilds Its Portfolio Around Earnings Momentum and De-rated Quality
Paradice Investment Management's September quarter reports record nine exits, including Wesfarmers, Goodman and Sonic, and new positions in Codan, REA Group, Telstra and Integral Diagnostics.
16 Nov 2026 · 4 min read

In short
Paradice Investment Management exited nine stocks in the September 2026 quarter, including Wesfarmers on the consumer outlook, Goodman Group on lofty growth expectations, Sonic Healthcare on German reform and Challenger on valuation.
It opened positions in Codan on earnings momentum, REA Group after a de-rating, Telstra for dependable earnings and Integral Diagnostics on signs that earnings growth is troughing.
Paradice added to CSL and Cochlear after what it called realistic rebasings of earnings expectations, bought Woodside as the Middle East conflict escalated, and trimmed Macquarie, QBE and EQ Resources.
Out of the consumer and the crowded
Paradice Investment Management used the September 2026 quarter to clear out positions where it saw the outlook or the expectations working against it. The most notable exit was Wesfarmers. Paradice, already underweight, sold out because “the higher rate outlook and slower housing turnover may dampen consumer spending,” according to its quarterly report.
Goodman Group went for a different reason. The industrial property and data centre developer was “exited as consensus growth expectations remained lofty in our view,” Paradice said. Sonic Healthcare was sold “on our concerns around German reform,” and Challenger was sold on valuation grounds, “with the stock trading close to its 52-week high following the FY26 result and upsized buyback.”
The manager also exited Mineral Resources as it moved into the S&P/ASX 50 Index, along with Beach Energy, Black Cat Syndicate and Regis Healthcare, for which the reports gave no reasons.
Exited as consensus growth expectations remained lofty in our view.
— Paradice Investment Management, Quarterly Report, September 2026
Life360: one fund holds, another sells
Life360 shows how Paradice's funds can reach different conclusions on the same company. In one September quarter report, Paradice said Life360 was the fund's largest detractor after a 29% fall following its June quarter result, despite revenue rising 38% and adjusted EBITDA rising 53%. That report described the issue as “a question of margin timing rather than a change in the investment thesis” and said “the reaction was disproportionate,” with Life360 remaining a large position.
Another Paradice report took the opposite step: “We sold our position in Life360 given our concerns about its ability to meet guidance in 2H26.”
Into earnings momentum and de-rated quality
The new positions fall into two groups. The first is momentum. Paradice bought Codan “on strong earnings momentum,” noting that it was added to the S&P/ASX 100 Index in the September rebalance and that, with demand strong across communications and metal detection, “the company upgraded its revenue guidance during the quarter, only a month after its FY26 result.”
The second group is quality businesses that have fallen. Paradice bought REA Group “following a significant de-rating on concerns around the impact of the Federal Budget on housing turnover and the broader SaaS sell-off.” “The FY26 result showed net profit up 15% despite flat listings, in our opinion, demonstrating the strength of the company's pricing power,” the manager said.
The FY26 result showed net profit up 15% despite flat listings, in our opinion, demonstrating the strength of the company's pricing power.
— Paradice Investment Management, Quarterly Report, September 2026
Telstra was added for its reliability. Paradice said the recently added position contributed “as the market appeared to reward its defensive, dependable earnings,” and described the company as “executing well, equipped with a solid balance sheet.” The manager also said it holds overweight positions in communication services stocks it sees as oversold on AI-related concerns. Integral Diagnostics, the radiology group, was bought on the view that earnings growth “looks to be troughing.”
Healthcare: CSL and Cochlear after the reset
Paradice's healthcare moves rest on the same phrase used twice. It increased CSL and Cochlear “post what we thought was, a realistic rebasing of earnings expectations,” with an improving revenue outlook.
On CSL, Paradice said it held no exposure through much of the stock's de-rating and initiated only recently. CSL then recovered over the quarter “as the market began to look through to its earnings recovery.” Paradice added: “We continue to anticipate reasonable value in the franchise over the medium term, though we are mindful that some earnings risk remains.”
On Cochlear, which moved out of the S&P/ASX 50 in the September rebalance, Paradice bought on its view “that the Nucleus Nexa System will drive a recovery in growth.”
We continue to anticipate reasonable value in the franchise over the medium term, though we are mindful that some earnings risk remains.
— Paradice Investment Management, Quarterly Report, September 2026
Energy, financials and resources
Paradice bought Woodside “as the Middle East conflict escalated through the quarter,” moving from an underweight position. It trimmed Macquarie Group after a period of strong outperformance and cut QBE on concerns about a slowdown in commercial insurance pricing and increased competition.
In smaller resources, Paradice initiated or added to Brazilian Critical Minerals, Meeka Metals and FINEOS, and took profits in tungsten producer EQ Resources after a 47% rise. Paradice said EQ's record September quarter revenue of A$158.8 million and its new US processing joint venture “strengthen EQR's position as a leading non-Chinese tungsten supplier,” while it continued “to manage risk in the position.”
What Paradice is watching
Paradice's September quarter leaves its portfolio leaning toward companies with rising earnings, such as Codan, and quality businesses it believes have reset expectations, such as CSL, Cochlear and REA Group. It has moved away from consumer exposure tied to housing and interest rates, and from Goodman, where it judged expectations too high. The manager's own caveats point to what it will be watching: whether CSL's earnings risk fades, whether Nucleus Nexa lifts Cochlear's growth, and, for Life360, whether second-half guidance is met.
Questions
Why did Paradice sell Wesfarmers?
Paradice Investment Management exited Wesfarmers in the September 2026 quarter because, in its view, the higher interest rate outlook and slower housing turnover may dampen consumer spending. It had already been underweight the stock.
What new positions did Paradice open in the September 2026 quarter?
Paradice Investment Management opened positions in Codan on strong earnings momentum, REA Group after a significant de-rating, Telstra for its defensive, dependable earnings and Integral Diagnostics on signs that earnings growth is troughing. It also added to CSL, Cochlear and Woodside.
Why did Paradice exit Goodman Group?
Paradice Investment Management exited Goodman Group in the September 2026 quarter because it judged that consensus growth expectations for the company remained lofty.
29 managers, 57 comments, with each manager's latest recorded position.
See WES